Zygomycosis in children: A systematic review and analysis of reported cases

Pediatric Infectious Disease Journal

Volumn 26, Issue 8, 2007, Pages 723-727

  Zaoutis, Theoklis E ^a,b   Roilides, Emmanuel ^c   Chiou, Christine C ^e   Buchanan, Wendy L ^d   Knudsen, Tena A ^d   Sarkisova, Tatyana A ^d   Schaufele, Robert L ^d   Sein, Michael ^d   Sein, Tin ^d   Prasad, Priya A ^b   Chu, Jaclyn H ^b   Walsh, Thomas J ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Epidemiology; Mucormycosis; Outcome; Risk factors; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; KETOCONAZOLE; POTASSIUM IODIDE; SODIUM IODIDE;

ADOLESCENT; ARTICLE; BRAIN INFECTION; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INFANT; KETOACIDOSIS; LOGISTIC REGRESSION ANALYSIS; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; MORTALITY; MUCOR; MUCORMYCOSIS; NEUTROPENIA; NEWBORN; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; RHIZOPUS; RISK FACTOR; SKIN INFECTION; SYSTEMATIC REVIEW;

EID: 34548732673     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/INF.0b013e318062115c     Document Type: Review

References (11)

1. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am. 2002;16:895-914.
2. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis. 2004;39:588-590.
3. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10(Suppl 1):31-47.
4. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350-1360.
5. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653.
6. Graubard BI KE. Analysis of Health Surveys. New York, NY: Wiley; 1999.
7. Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis. 1994; 19:67-76. (references 8-120 are available online only).
8. Starke JR, Mason EO Jr, Kramer WG, Kaplan SL. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis. 1987;155:766-774.
9. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006;42:1726-1734.
10. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:e61-e65.
11. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis. 2005;40:1684-1688.